Expression of Acetylcholine and Its Receptor in Human Sympathetic Ganglia in Primary Hyperhidrosis

Júnior, Nabor B. de Moura; Das-Neves-Pereira, João Carlos; Oliveira, Flávio Roberto Garbelini de; Jatene, Fábio Biscegli; Parra, Edwin Roger; Capelozzi, Vera Luíza; Wolosker, Nelson; Campos, José Ribas Milanez de

doi:10.1016/j.athoracsur.2012.10.068

Cited by 36 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was demonstrated that patients with primary hyperhidrosis have a higher expression of acetylcholine and alpha-7 nicotinic receptors in sympathetic ganglia. ( 5 ) Oxybutynin is an antimuscarinic drug that was first associated to hyperhidrosis in 1988. ( 6 ) In the second half of the last decade, specific treatment with this drug began to be reported.…”

Section: Introductionmentioning

confidence: 99%

Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years

Wolosker

Krutman

Teivelis

et al. 2014

Einstein (São Paulo)

Self Cite

View full text Add to dashboard Cite

Objective:Our aim was to analyze the effectiveness of oxybutynin for hyperhidrosis treatment in patients over 40 years.Methods:Eighty-seven patients aged over 40 years were divided into two groups. One group consisted of 48 (55.2%) patients aged between 40 and 49 years, and another was composed of 39 (44.8%) patients aged over 50 years (50 to 74 years). A comparative analysis of Quality of Life and level of hyperhidrosis between the groups was carried out 6 weeks after a protocol treatment with oxybutynin. A validated clinical questionnaire was used for evaluation.Results:In the younger age group, 75% of patients referred a “partial” or “great” improvement in level of hyperhidrosis after treatment. This number was particularly impressive in patients over 50 years, in which 87.2% of the cases demonstrated similar levels of improvement. Over 77% of patients in both groups demonstrated improvement in Quality of Life. Excellent outcomes were observed in older patients, in which 87.1% of patients presented “slightly better” (41%) or “much better” (46.1%) improvement.Conclusion:Patients aged over 40 years with hyperhidrosis presented excellent results after oxybutynin treatment. These outcomes were particularly impressive in the age group over 50 years, in which most patients had significant improvement in Quality of Life and in level of hyperhidrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years

Wolosker

Krutman

Teivelis

et al. 2014

Einstein (São Paulo)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with primary hyperhidrosis have higher‐than‐normal numbers of acetylcholine and alpha‐7 nicotinic receptors on the sympathetic ganglia . Oxybutynin is an antimuscarinic drug that was first associated with the resolution of hyperhidrosis in 1988 .…”

mentioning

confidence: 99%

Long‐Term Efficacy of Oxybutynin for Palmar and Plantar Hyperhidrosis in Children Younger than 14 Years

Wolosker

Teivelis

Krutman

et al. 2014

Pediatric Dermatology

Self Cite

View full text Add to dashboard Cite

Oxybutynin for treating hyperhidrosis in children has been evaluated only in short-term studies. We aimed to investigate the long-term effects of oxybutynin in treating children with palmar and plantar hyperhidrosis who had not undergone surgery and who were monitored for at least 6 months (median 19.6 mos). A cohort of 97 patients was evaluated retrospectively, with particular attention to 59 children (ages 4-14 yrs) who were treated for longer than 6 months. Their quality of life (QOL) was evaluated using a validated clinical questionnaire before and after 6 weeks of pharmacologic therapy. A self-assessment of hyperhidrosis was performed after 6 weeks and after the last consultation. By their final office visit, more than 91% of the children with hyperhidrosis treated with oxybutynin experienced moderate or great improvement in their level of sweating and 94.9% experienced improvement in QOL. More than 90% of children reported improvement of hyperhidrosis at other sites. Dry mouth was the most common side effect. Oxybutynin appears to be an effective treatment option for children with hyperhidrosis, and positive results are maintained over the long term (median 19.6 mos).

show abstract

“…Recent research involving the immunohistochemical analysis of sympathetic ganglia of HH patients versus organ donor controls without history of HH demonstrates significantly higher expression of acetylcholine receptors ( P <0.001) and significantly larger sympathetic chain ganglia ( P <0.001) in the former group 15. These fascinating findings by de Moura Júnior et al15 may elucidate a more concrete pathophysiologic explanation for HH.…”

Section: Introductionmentioning

confidence: 90%

“…Sweating associated with primary HH may be related to a dysfunction of the sympathetic nervous system and hypothalamus, coupled with input from the anterior cingulate cortex10 of the limbic system,13,14 possibly explaining the relationship between certain stimuli (such as emotions) and exacerbation of HH symptom manifestation 10. Recent research involving the immunohistochemical analysis of sympathetic ganglia of HH patients versus organ donor controls without history of HH demonstrates significantly higher expression of acetylcholine receptors ( P <0.001) and significantly larger sympathetic chain ganglia ( P <0.001) in the former group 15. These fascinating findings by de Moura Júnior et al15 may elucidate a more concrete pathophysiologic explanation for HH.…”

Section: Introductionmentioning

confidence: 99%

Management of hyperhidrosis

Stashak¹,

Brewer

2014

CCID

View full text Add to dashboard Cite

Primary hyperhidrosis (HH), a condition of sweating in excess of thermoregulatory requirements, affects nearly 3% of the US population and carries significant emotional and psychosocial implications. Unlike secondary HH, primary HH is not associated with an identifiable underlying pathology. Our limited understanding of the precise pathophysiologic mechanism for HH makes its treatment particularly frustrating. However, a wide array of interventions for the treatment of HH have been implemented throughout the world. Herein, we discuss the most extensively studied therapeutic options for primary HH, including systemic oxybutynin, botulinum toxin injections, skin excision, liposuction–curettage, and sympathotomy/sympathectomy. We conclude with a discussion of possible future therapies for HH, including the applications of laser, microwave, and ultrasound technologies.

show abstract

Expression of Acetylcholine and Its Receptor in Human Sympathetic Ganglia in Primary Hyperhidrosis

Cited by 36 publications

References 20 publications

Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years

Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years

Long‐Term Efficacy of Oxybutynin for Palmar and Plantar Hyperhidrosis in Children Younger than 14 Years

Management of hyperhidrosis

Contact Info

Product

Resources

About